Financial Analysis: Nutriband (NTRB) and The Competition

Nutriband (NASDAQ:NTRB) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Nutriband to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.

Profitability

This table compares Nutriband and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Nutriband Competitors	-2,372.59%	-220.83%	-15.99%

Analyst Ratings

This is a summary of current ratings and price targets for Nutriband and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Nutriband Competitors	7769	13856	25724	1032	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.89%. Given Nutriband’s peers stronger consensus rating and higher probable upside, analysts plainly believe Nutriband has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Nutriband and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nutriband	$2.04 million	-$8.23 million	-11.87
Nutriband Competitors	$3.55 billion	$3.17 billion	547.95

Nutriband’s peers have higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Nutriband has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Nutriband’s peers have a beta of -3.79, meaning that their average share price is 479% less volatile than the S&P 500.

Summary

Nutriband peers beat Nutriband on 9 of the 13 factors compared.

Nutriband Company Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.